These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

573 related items for PubMed ID: 24632604

  • 1. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
    Yang J, Kalogerou M, Samsel PA, Zhang Y, Griffiths DF, Gallacher J, Sampson JR, Shen MH.
    Oncogene; 2015 Feb 12; 34(7):922-31. PubMed ID: 24632604
    [Abstract] [Full Text] [Related]

  • 2. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells.
    Alayev A, Sun Y, Snyder RB, Berger SM, Yu JJ, Holz MK.
    Cell Cycle; 2014 Feb 12; 13(3):371-82. PubMed ID: 24304514
    [Abstract] [Full Text] [Related]

  • 3. Fetal brain mTOR signaling activation in tuberous sclerosis complex.
    Tsai V, Parker WE, Orlova KA, Baybis M, Chi AW, Berg BD, Birnbaum JF, Estevez J, Okochi K, Sarnat HB, Flores-Sarnat L, Aronica E, Crino PB.
    Cereb Cortex; 2014 Feb 12; 24(2):315-27. PubMed ID: 23081885
    [Abstract] [Full Text] [Related]

  • 4. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
    Gordon BS, Kazi AA, Coleman CS, Dennis MD, Chau V, Jefferson LS, Kimball SR.
    Cell Signal; 2014 Mar 12; 26(3):461-7. PubMed ID: 24316235
    [Abstract] [Full Text] [Related]

  • 5. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
    Kim SH, Kowalski ML, Carson RP, Bridges LR, Ess KC.
    Dis Model Mech; 2013 Jul 12; 6(4):925-33. PubMed ID: 23580196
    [Abstract] [Full Text] [Related]

  • 6. Growth-factor dependent expression of the translationally controlled tumour protein TCTP is regulated through the PI3-K/Akt/mTORC1 signalling pathway.
    Bommer UA, Iadevaia V, Chen J, Knoch B, Engel M, Proud CG.
    Cell Signal; 2015 Aug 12; 27(8):1557-68. PubMed ID: 25936523
    [Abstract] [Full Text] [Related]

  • 7. mTORC2 is required for proliferation and survival of TSC2-null cells.
    Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, Krymskaya VP.
    Mol Cell Biol; 2011 Jun 12; 31(12):2484-98. PubMed ID: 21482669
    [Abstract] [Full Text] [Related]

  • 8. Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα).
    Dan HC, Ebbs A, Pasparakis M, Van Dyke T, Basseres DS, Baldwin AS.
    J Biol Chem; 2014 Sep 05; 289(36):25227-40. PubMed ID: 24990947
    [Abstract] [Full Text] [Related]

  • 9. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
    Huang J, Wu S, Wu CL, Manning BD.
    Cancer Res; 2009 Aug 01; 69(15):6107-14. PubMed ID: 19602587
    [Abstract] [Full Text] [Related]

  • 10. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M, Gillick JL, Neil J, Tobias M, Thwing ZE, Murali R.
    Adv Biol Regul; 2015 Jan 01; 57():64-74. PubMed ID: 25442674
    [Abstract] [Full Text] [Related]

  • 11. Serine 302 Phosphorylation of Mouse Insulin Receptor Substrate 1 (IRS1) Is Dispensable for Normal Insulin Signaling and Feedback Regulation by Hepatic S6 Kinase.
    Copps KD, Hançer NJ, Qiu W, White MF.
    J Biol Chem; 2016 Apr 15; 291(16):8602-17. PubMed ID: 26846849
    [Abstract] [Full Text] [Related]

  • 12. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
    Peng H, Liu J, Sun Q, Chen R, Wang Y, Duan J, Li C, Li B, Jing Y, Chen X, Mao Q, Xu KF, Walker CL, Li J, Wang J, Zhang H.
    Oncogene; 2013 Sep 26; 32(39):4702-11. PubMed ID: 23108404
    [Abstract] [Full Text] [Related]

  • 13. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway.
    Zhang HH, Huang J, Düvel K, Boback B, Wu S, Squillace RM, Wu CL, Manning BD.
    PLoS One; 2009 Jul 10; 4(7):e6189. PubMed ID: 19593385
    [Abstract] [Full Text] [Related]

  • 14. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
    Cao J, Tyburczy ME, Moss J, Darling TN, Widlund HR, Kwiatkowski DJ.
    J Clin Invest; 2017 Jan 03; 127(1):349-364. PubMed ID: 27918305
    [Abstract] [Full Text] [Related]

  • 15. Critical role of SCD1 in autophagy regulation via lipogenesis and lipid rafts-coupled AKT-FOXO1 signaling pathway.
    Tan SH, Shui G, Zhou J, Shi Y, Huang J, Xia D, Wenk MR, Shen HM.
    Autophagy; 2014 Feb 03; 10(2):226-42. PubMed ID: 24296537
    [Abstract] [Full Text] [Related]

  • 16. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
    Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E.
    PLoS One; 2013 Feb 03; 8(2):e57289. PubMed ID: 23437362
    [Abstract] [Full Text] [Related]

  • 17. Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy.
    Huang H, Kang R, Wang J, Luo G, Yang W, Zhao Z.
    Autophagy; 2013 Feb 01; 9(2):175-95. PubMed ID: 23169238
    [Abstract] [Full Text] [Related]

  • 18. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
    Jin F, Jiang K, Ji S, Wang L, Ni Z, Huang F, Li C, Chen R, Zhang H, Hu Z, Zha X.
    Hum Mol Genet; 2017 Jan 15; 26(2):407-419. PubMed ID: 28013293
    [Abstract] [Full Text] [Related]

  • 19. mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells.
    Liu J, Stevens PD, Gao T.
    J Biol Chem; 2011 Feb 25; 286(8):6510-20. PubMed ID: 21177869
    [Abstract] [Full Text] [Related]

  • 20. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.
    Harada K, Miyake H, Kumano M, Fujisawa M.
    Br J Cancer; 2013 Oct 29; 109(9):2389-95. PubMed ID: 24091619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.